Manages manifestations of psychotic disorders. ANDA 213368, held by Zydus Lifesciences. Chlorpromazine Hydrochloride.
As of Nov 16, 2026, ANDA 213368 (Chlorpromazine Hydrochloride), held by Zydus Lifesciences, was first approved by FDA on Jan 17, 2020, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 17, 2020 | Original application | Approved | None posted |
| Chlorpromazine Hydrochloride10MG · tablet;oral | Chlorpromazine Hydrochloride | Rx |
| Chlorpromazine Hydrochloride25MG · tablet;oral | Chlorpromazine Hydrochloride | Rx |
| Chlorpromazine Hydrochloride50MG · tablet;oral | Chlorpromazine Hydrochloride | Rx |
| Chlorpromazine Hydrochloride100MG · tablet;oral | Chlorpromazine Hydrochloride | Rx |
| Chlorpromazine Hydrochloride200MG · tablet;oral | Chlorpromazine Hydrochloride | Rx |
| Mar 15, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 17, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters